Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John F Forbes

Showing results (61-70 of 85) with videos related to

Pageof 9
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 25, 2016
Treatment Adherence and Its Impact on Disease-Free Survival in the Breast International Group 1-98 Trial of Tamoxifen and Letrozole, Alone and in SequenceJacquie H Chirgwin, Anita Giobbie-Hurder, Alan S Coates, et al.
Lancet (London, England)|May 4, 2013
Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant dataJack Cuzick, Ivana Sestak, Bernardo Bonanni, et al.
Breast Cancer Research and Treatment|October 28, 2008
Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93Olivia Pagani, Shari Gelber, Edda Simoncini, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 16, 2011
Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 studyMarco Colleoni, Anita Giobbie-Hurder, Meredith M Regan, et al.
European Journal of Cancer (Oxford, England : 1990)|May 12, 2017
HER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2John M S Bartlett, Ikhlaaq Ahmed, Meredith M Regan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 10, 2012
Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trialMarianne Ewertz, Kathryn P Gray, Meredith M Regan, et al.
JAMA Internal Medicine|April 14, 2015
Increased Hospital-Based Physical Rehabilitation and Information Provision After Intensive Care Unit Discharge: The RECOVER Randomized Clinical TrialTimothy S Walsh, Lisa G Salisbury, Judith L Merriweather, et al.
The Lancet. Diabetes & Endocrinology|March 14, 2014
Effect of a lifestyle intervention on weight change in south Asian individuals in the UK at high risk of type 2 diabetes: a family-cluster randomised controlled trialRaj S Bhopal, Anne Douglas, Sunita Wallia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 29, 2008
Recommendations for collection and handling of specimens from group breast cancer clinical trialsBrian R Leyland-Jones, Christine B Ambrosone, John Bartlett, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 11, 2007
The role of the number of uninvolved lymph nodes in predicting locoregional recurrence in breast cancerPer Karlsson, Bernard F Cole, Karen N Price, et al.
Pageof 9

Showing results (61-70 of 85) with videos related to

Sort By:
Pageof 9
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 25, 2016
Treatment Adherence and Its Impact on Disease-Free Survival in the Breast International Group 1-98 Trial of Tamoxifen and Letrozole, Alone and in SequenceJacquie H Chirgwin, Anita Giobbie-Hurder, Alan S Coates, et al.
Lancet (London, England)|May 4, 2013
Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant dataJack Cuzick, Ivana Sestak, Bernardo Bonanni, et al.
Breast Cancer Research and Treatment|October 28, 2008
Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93Olivia Pagani, Shari Gelber, Edda Simoncini, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 16, 2011
Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 studyMarco Colleoni, Anita Giobbie-Hurder, Meredith M Regan, et al.
European Journal of Cancer (Oxford, England : 1990)|May 12, 2017
HER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2John M S Bartlett, Ikhlaaq Ahmed, Meredith M Regan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 10, 2012
Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trialMarianne Ewertz, Kathryn P Gray, Meredith M Regan, et al.
JAMA Internal Medicine|April 14, 2015
Increased Hospital-Based Physical Rehabilitation and Information Provision After Intensive Care Unit Discharge: The RECOVER Randomized Clinical TrialTimothy S Walsh, Lisa G Salisbury, Judith L Merriweather, et al.
The Lancet. Diabetes & Endocrinology|March 14, 2014
Effect of a lifestyle intervention on weight change in south Asian individuals in the UK at high risk of type 2 diabetes: a family-cluster randomised controlled trialRaj S Bhopal, Anne Douglas, Sunita Wallia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 29, 2008
Recommendations for collection and handling of specimens from group breast cancer clinical trialsBrian R Leyland-Jones, Christine B Ambrosone, John Bartlett, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 11, 2007
The role of the number of uninvolved lymph nodes in predicting locoregional recurrence in breast cancerPer Karlsson, Bernard F Cole, Karen N Price, et al.
Pageof 9